Oct 02, 2019 8:30am EDT SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Sep 18, 2019 8:30am EDT SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
Aug 07, 2019 4:15pm EDT SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
Jul 31, 2019 8:00am EDT SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
Jul 24, 2019 8:00am EDT SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
Jun 25, 2019 8:30am EDT World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
Jun 05, 2019 8:30am EDT SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections
May 30, 2019 8:30am EDT SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
